1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Roche Battered By Biosimilars But Holds On To Initial Forecast

Still Expects CHF4.6bn Impact From Biosimilar Competition For 2021

 
• By Dean Rudge

Roche insisted that “biosimilar competition is only one factor in the overall picture,” as it reported another set of depleted figures for its three powerhouse biologic brands: Avastin, MabThera/Rituxan and Herceptin.

Roche
Roche expects Lucentis competition in 2021 • Source: Shutterstock

Roche described “a very significant impact of CHF2.8bn ($3.04bn)” from biosimilar competition to Avastin (bevacizumab), MabThera/Rituxan (rituximab) and Herceptin (trastuzumab) in the first half of 2021, although the originator maintains the impact will “decline as expected in the second half of this year.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products